Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
for Atherosclerotic Cardiovascular Disease (ASCVD)
Drug: Inclisiran
37 locations incl. Birmingham
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 18 - 80
Code: NCT06813911·Phase 3·Recruiting